MARASCA, Roberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 36.272
AS - Asia 15.043
EU - Europa 12.869
SA - Sud America 1.927
Continente sconosciuto - Info sul continente non disponibili 579
AF - Africa 321
OC - Oceania 54
Totale 67.065
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 35.375
GB - Regno Unito 4.464
HK - Hong Kong 3.709
SG - Singapore 3.590
CN - Cina 3.404
IT - Italia 2.554
VN - Vietnam 1.518
BR - Brasile 1.461
SE - Svezia 1.224
DE - Germania 1.050
FI - Finlandia 923
BD - Bangladesh 775
RU - Federazione Russa 618
UA - Ucraina 531
FR - Francia 463
CA - Canada 440
TR - Turchia 436
KR - Corea 309
IN - India 295
ID - Indonesia 225
BG - Bulgaria 212
NL - Olanda 146
AR - Argentina 139
MX - Messico 119
JP - Giappone 108
IQ - Iraq 107
ES - Italia 97
IE - Irlanda 93
EC - Ecuador 79
PL - Polonia 77
PK - Pakistan 71
ZA - Sudafrica 71
CZ - Repubblica Ceca 67
AE - Emirati Arabi Uniti 64
CL - Cile 61
CO - Colombia 57
BE - Belgio 56
CR - Costa Rica 56
PH - Filippine 53
AT - Austria 52
AU - Australia 51
VE - Venezuela 49
IL - Israele 48
JM - Giamaica 48
MA - Marocco 48
MY - Malesia 44
LT - Lituania 42
KE - Kenya 35
UZ - Uzbekistan 34
SA - Arabia Saudita 33
PR - Porto Rico 30
TN - Tunisia 30
HN - Honduras 29
SC - Seychelles 27
TT - Trinidad e Tobago 27
DZ - Algeria 26
EG - Egitto 26
PY - Paraguay 26
RO - Romania 26
SV - El Salvador 25
IR - Iran 24
AZ - Azerbaigian 22
NI - Nicaragua 22
PE - Perù 22
BZ - Belize 20
CH - Svizzera 20
GT - Guatemala 20
JO - Giordania 20
TW - Taiwan 19
GP - Guadalupe 18
SK - Slovacchia (Repubblica Slovacca) 17
BO - Bolivia 16
NP - Nepal 16
PT - Portogallo 16
DK - Danimarca 15
EU - Europa 15
ET - Etiopia 14
TH - Thailandia 14
UY - Uruguay 14
CW - ???statistics.table.value.countryCode.CW??? 13
RS - Serbia 13
AL - Albania 12
EE - Estonia 11
KZ - Kazakistan 11
LB - Libano 11
SI - Slovenia 11
DO - Repubblica Dominicana 10
QA - Qatar 10
BY - Bielorussia 9
CY - Cipro 9
GR - Grecia 9
SN - Senegal 9
OM - Oman 8
PS - Palestinian Territory 8
BH - Bahrain 7
KW - Kuwait 7
LK - Sri Lanka 7
LV - Lettonia 7
MD - Moldavia 7
SY - Repubblica araba siriana 7
Totale 66.393
Salva come PNG Salva come JPEG
Città #
Ashburn 4.313
Hong Kong 3.673
Fairfield 3.249
Southend 3.187
Santa Clara 2.495
Singapore 2.235
Woodbridge 1.879
Ann Arbor 1.651
Houston 1.507
Chandler 1.449
San Jose 1.316
Seattle 1.276
Wilmington 1.074
Council Bluffs 1.059
Cambridge 1.018
Hefei 984
Jacksonville 983
Dearborn 839
Nyköping 746
Helsinki 706
London 657
Los Angeles 620
Beijing 603
New York 507
Chicago 505
Ho Chi Minh City 505
Modena 431
The Dalles 383
Hanoi 319
San Diego 310
Milan 293
Buffalo 292
Seoul 292
Princeton 251
Izmir 228
Sofia 209
Lauterbourg 193
Boardman 191
Eugene 189
Salt Lake City 189
Munich 185
Dallas 169
Moscow 157
Jakarta 155
Columbus 152
São Paulo 147
Shanghai 135
Rome 129
Fremont 113
Toronto 110
Phoenix 109
Bologna 106
North Bergen 104
Tampa 104
Frankfurt am Main 102
Bremen 90
Orem 88
Dublin 84
Elk Grove Village 81
Tokyo 80
Atlanta 79
Redwood City 79
Brooklyn 77
Montreal 77
Da Nang 71
Des Moines 68
Miami 68
Haiphong 64
Dong Ket 57
Naples 57
Warsaw 55
Nuremberg 54
Philadelphia 54
Chennai 52
Brussels 50
Denver 50
Guangzhou 50
Falls Church 49
Lancaster 48
San Francisco 47
Washington 46
Baghdad 45
Norwalk 45
Kent 44
Newark 44
Brno 42
Rio de Janeiro 41
Las Vegas 40
Stockholm 37
Kunming 36
Vancouver 36
Miano 35
San José 34
Amsterdam 33
Boston 33
Mexico City 33
Reggio Emilia 33
Turku 33
Parma 32
Johannesburg 31
Totale 47.165
Salva come PNG Salva come JPEG
Nome #
Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. 847
Monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation 618
Lenalidomide in Pretreated Mantle Cell Lymphoma Patients: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice (the Lenamant Study) 592
Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor 463
Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients 461
Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study 451
SVILUPPO DI IPOGAMMAGLOBULINEMIA IN PAZIENTI TRATTATI CON IMATINIB PER LEUCEMIA MIELOIDE CRONICA O TUMORI STROMALI GASTROINTESTINALI 449
Lack of confirmation of an association between HTLV-I infection and myelodysplastic syndrome 426
BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors 425
Bone marrow failure associated with human herpesvirus 8 infection after transplantation 424
An unusual case of B-ALL occurring in a patient with acute promyelocytic leukemia in remission after two hematopoietic SCTs: whose are the leukemic cells? 416
The expression of endothelin-1 in chronic lymphocytic leukemia is controlled by epigenetic mechanisms and extracellular stimuli. 415
NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms 399
Mucorales-specific T cells in patients with hematologic malignancies 394
Acute myeloid leukemia in patients living with HIV infection: Several questions, fewer answers 392
Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia 391
Chronic/relapsing lymphadenopathy associated with HHV-6B infection: a new benign clinico-pathologic entity occurring in immunocompetent individuals 390
3 CASES OF HUMAN HERPESVIRUS-6 LATENT INFECTION - INTEGRATION OF VIRAL GENOME IN PERIPHERAL-BLOOD MONONUCLEAR CELL-DNA 380
Human herpesvirus-8 DNA sequences in Human Immunodeficiency Virus-negative angioimmunoblastic lymphadenopathy and benign lymphadenopathy with giant germinal center hyperplasia and increased vascularity 379
Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia 379
Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study 377
Selective inhibition of PI3Kγ affects survival and proliferation of chronic lymphocytic leukemia B cells 375
Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide 374
Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials 373
A case of JAK2 V617F-positive myelodysplastic/myeloproliferative neoplasm with unusual morphology, resembling acute promyelocytic leukemia-like disorder with a chronic course. 372
Chronic myeloid leukemia with thrombocythemic onset may be associated with different BCR/ABL variant transcripts 370
Characterization and dynamics of specific T cells against nucleophosmin-1 (NPM1)-mutated peptides in patients with NPM1-mutated acute myeloid leukemia 368
Gene expression profiling of acute promyelocytic leukaemia identifies two subtypes mainly associated with Flt3 mutational status 366
Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia 364
Detection of Fusarium-specific T cells in hematologic patients with invasive fusariosis 363
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 361
Antineoplastic effects of liposomal siRNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma 358
The genetics of nodal marginal zone lymphoma 358
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 357
Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura. 354
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 353
Endothelin-1 promotes survival and chemoresistance in chronic lymphocytic leukemia B cells through eta receptor 353
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 351
Increased angiogenesis induced by chronic lymphocytic leukemia B cells is mediated by leukemia-derived Ang2 and VEGF. 348
Physical contact with endothelial cells through β1- and β2- integrins rescues chronic lymphocytic leukemia from spontaneous and drug-induced apoptosis and induces a peculiar gene expression profile on leukemic cells. 346
Chronic eosinophilic leukaemia with ETV6-NTRK3 fusion transcript in an elderly patient affected with pancreatic carcinoma 345
B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: The growing saga of the IGHV3 subgroup gene usage 345
Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. 344
All-trans retinoic acid (ATRA) in non-promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low-dose Ara-C in three elderly patients with NPM1-mutated AML unfit for intensive chemotherapy and review of the literature 343
Peripheral lymphadenopathy: role of excisional biopsy in differential diagnosis based on a five-year experience. 342
Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia 342
Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. 338
Missense mutations in the PML/RAR alpha ligand binding domain in ATRA-resistant As2O3 sensitive relapsed acute promyelocytic leukemia 337
INTERACTION BETWEEN ENDOTHELIUM AND CHRONIC LYMPHOCYTIC LEUKEMIA B-CELLS RESCUES FROM APOPTOSIS AND MODULATES GENE EXPRESSION PROFILE OF LEUKEMIC CELLS 334
Increased expression of angiopoietin-2 characterizes early B-cell chronic lymphocytic leukemia with poor prognosis 333
Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding 332
Atraumatic splenic rupture in patients with myelodysplastic syndromes: Report of a case occurred during treatment with 5-azacitidine and review of the literature. 331
Additional neoplasms and HCV infection in low-grade lymphoma of MALT type 331
P53 GENE POINT MUTATIONS IN RELATION TO P53 NUCLEAR-PROTEIN ACCUMULATION IN COLORECTAL CANCERS 330
Angiopoietin-2 expression in B-cell chronic lymphocytic leukemia: association with clinical outcome and immunoglobulin heavy-chain mutational status 329
Investigating the association between physicians self-efficacy regarding communication skills and risk of “burnout” 329
Immunoglobulin gene mutations and frequent use of VH1-69 and VH4-34 segments in hepatitis C virus-positive and hepatitis C virus-negative nodal marginal zone B-cell lymphoma 328
Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience 328
The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungi 328
Identification and characterization of Aspergillus-specific immune responses to diagnose invasive aspergillosis in high risk patients: a multicenter study 326
Chronic and recurrent benign lymphadenopathy without constitutional symptoms associated with human herpesvirus-6B reactivation 326
ANGPT2 promoter methylation is strongly associated with gene expression and prognosis in chronic lymphocytic leukemia 325
Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia 322
Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections 322
Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. 320
Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study 320
BCR-ABL-specific cytotoxic T cells in the bone marrow of patients with Ph(+) acute lymphoblastic leukemia during second-generation tyrosine-kinase inhibitor therapy. 319
Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance 319
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. 317
The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. 317
Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma 316
Angiopoietin-2 acts as a survival factor for chronic lymphocytic leukemia B cells throughout Tie-2 receptor engagement 316
Macitentan, a double antagonist of endothelin receptors, efficiently impairs migration and microenvironmental survival signals in chronic lymphocytic leukemia 313
Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience 309
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival 308
Ruxolitinib for pulmonary extramedullary hematopoiesis in myelofibrosis 307
NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL 303
Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes 303
Circulating functional T cells specific to human herpes virus 6 (HHV6) antigens in individuals with chromosomally integrated HHV6 302
May the indirect effects of CIHHV-6 in transplant patients be exerted through the reactivation of the viral replicative machinery? 302
Randomized phase 2 study: Elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM 301
Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study 301
The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development 300
Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia 300
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia 299
The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells 298
Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib 298
Immunoglobulin mutational status detected through single-round amplification of partial VH region, represents a good prognostic marker for the clinical outcome in chronic lymphocytic leukemia 298
A variant of the LRP4 gene affects the risk of chronic lymphocytic leukaemia transformation to Richter syndrome 298
The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1- PDGFRB rearrangement and overview of PDGFRB partner genes 297
Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation 297
Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia 295
Targeted integration of human herpesvirus 6 in the p arm of chromosome 17 of human peripheral blood mononuclear cells in vivo 295
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 294
Strikingly homologous immunoglobulin gene rearrangements and poor outcome inV(H)3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status 294
HOXA homeogene cluster interruption and dysregulation of HOAX9 in the blast crisis of Philadelphia chromosome-positive chronic myeloid leukemia. 293
Severe anemia in a patient with multiple sclerosis treated with natalizumab 293
Distinct genomic events in the myeloid and lymphoid lineages in simultaneous presentation of chronic myeloid leukemia and B-chronic lymphocytic leukemia 291
BTK Inhibitors Impair Platelet-Mediated Antifungal Activity 291
Gestational thrombocytopenia - Reply 290
Totale 35.236
Salva come PNG Salva come JPEG
Categoria #
all - tutte 264.553
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 264.553
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.807 0 0 0 0 99 235 259 192 398 307 698 619
2022/20234.255 503 482 325 374 579 570 81 445 488 51 190 167
2023/20242.972 104 162 172 272 562 270 349 452 54 68 188 319
2024/202510.787 313 123 141 682 1.580 1.278 624 450 2.867 445 985 1.299
2025/202619.305 1.227 1.274 1.683 2.054 2.619 1.259 2.284 924 1.739 1.613 1.624 1.005
2026/20276.019 628 1.060 1.493 2.403 435 0 0 0 0 0 0 0
Totale 67.065